Centre for Applied Health Economics, Griffith University, Nathan, Queensland, Australia.
School of Accounting, Finance & Economics, Griffith University, Nathan, Queensland, Australia.
PLoS One. 2024 Sep 6;19(9):e0307116. doi: 10.1371/journal.pone.0307116. eCollection 2024.
This work explores if behaviour-based asymmetries are likely to impact deal valuation in the life sciences by examining positive public sentiment as a proxy for market behaviour when negotiating under asymmetric conditions to examine heterogeneity in research & development collaboration (RDC) deal data. We use public sentiment as a proxy for behaviour along with stage of development-based RDC deal data to search for latent classes in the deal data using finite mixture modelling. The analysis reveals a nuanced picture: public sentiment emerges as a significant predictor of deal value, but only for approximately 15% of the data set. This subset exclusively includes firms in the Preclinical stage, where projects have moved past discovery but are yet to commence human studies. Interestingly, the research finds that sentiment's impact on deal valuation is particularly pronounced in this stage, suggesting heightened market sensitivity. With recent research demonstrating that knowledge asymmetry and behaviour impact valuation volatility, we take this further by capturing latent classes within the data which demonstrates how behaviour is most influential in deal pricing considerations. We argue that our research demonstrates the impact of asymmetry and market behaviour on a subset of RDCs where products are known, but likelihood of success is difficult to determine.
这项工作通过考察在不对称谈判条件下,积极的公众情绪是否可以作为市场行为的代理指标,来研究基于行为的不对称是否会影响生命科学领域的交易估值。我们使用公众情绪作为行为的代理指标,结合基于研发合作(RDC)交易数据的开发阶段,使用有限混合模型在交易数据中搜索潜在类别。分析揭示了一个微妙的情况:公众情绪成为交易价值的重要预测因素,但仅适用于数据集的大约 15%。这个子集专门包括处于临床前阶段的公司,这些项目已经超越了发现阶段,但尚未开始人体研究。有趣的是,研究发现,情绪对交易估值的影响在这个阶段尤为明显,表明市场敏感度更高。最近的研究表明,知识不对称和行为会影响估值波动性,我们通过在数据中捕获潜在类别进一步证明了这一点,这表明行为在交易定价考虑中最具影响力。我们认为,我们的研究表明,在产品已知但成功可能性难以确定的 RDC 子集中,不对称和市场行为对交易估值具有影响。